.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED03_Alectinib.Alectinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED03_Alectinib.Alectinib| name: | Alectinib | |
| ATC code: | L01ED03 | route: | oral |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 475 | L |
| clearance: | 81.9 | L/h |
| other parameters in model implementation | ||
Alectinib is an orally active, highly selective, and potent anaplastic lymphoma kinase (ALK) inhibitor used mainly in the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is approved by regulatory agencies including the FDA and EMA for this indication.
Pharmacokinetic parameters reported in adult patients with ALK-positive non-small cell lung cancer under fasted or fed conditions.
van der Heijden, LT, et al., & Dorlo, TPC (2023). The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib. Clinical and translational science 16(12) 2557–2564. DOI:10.1111/cts.13647 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37828717